Study of MR-107A-02 for the Treatment of Acute Postoperative Pain Following Herniorrhaphy

PHASE3CompletedINTERVENTIONAL
Enrollment

579

Participants

Timeline

Start Date

December 29, 2023

Primary Completion Date

January 31, 2025

Study Completion Date

March 12, 2025

Conditions
Acute PainPost Operative PainPain
Interventions
DRUG

MR-107A-02

tablet

DRUG

Tramadol

over-encapsulated tablet

DRUG

Placebo

over-encapsulated tablet and/or tablet

Trial Locations (18)

30331

Investigator site 207, Atlanta

33014

Investigator site 211, Miami

33613

Investigator site 206, Tampa

35660

Investigator site 210, Sheffield

54701

Investigator site 224, Eau Claire

67214

Investigator site 205, Wichita

75006

Investigator site 215, Carrollton

77008

Investigator site 204, Houston

77401

Investigator site 212, Bellaire

78229

Investigator site 219, San Antonio

78240

Investigator site 203, San Antonio

78258

Investigator site 214, San Antonio

78501

Investigator site 216, McAllen

84107

Investigator site 201, Salt Lake City

85053

Investigator site 213, Phoenix

92501

Investigator site 208, Riverside

92801

Investigator site 202, Anaheim

93301

Investigator site 222, Bakersfield

All Listed Sponsors
collaborator

Mylan Specialty, LP

INDUSTRY

lead

Viatris Specialty LLC

INDUSTRY

NCT06215859 - Study of MR-107A-02 for the Treatment of Acute Postoperative Pain Following Herniorrhaphy | Biotech Hunter | Biotech Hunter